Natera, Inc. $NTRA Stock Position Trimmed by Prudential Financial Inc.

Prudential Financial Inc. decreased its position in Natera, Inc. (NASDAQ:NTRA) by 68.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 90,310 shares of the medical research company’s stock after selling 198,699 shares during the period. Prudential Financial Inc. owned approximately 0.07% of Natera worth $15,257,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in shares of Natera during the first quarter valued at approximately $29,000. TCTC Holdings LLC grew its holdings in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after buying an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 106 shares in the last quarter. Hilltop National Bank bought a new stake in Natera during the 2nd quarter valued at $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera during the second quarter valued at $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on NTRA shares. JPMorgan Chase & Co. boosted their price target on Natera from $240.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 price target for the company in a report on Monday, October 27th. Morgan Stanley upped their target price on shares of Natera from $195.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Piper Sandler increased their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $220.88.

Natera Stock Performance

NTRA opened at $237.12 on Thursday. The business’s 50-day simple moving average is $190.07 and its 200 day simple moving average is $169.57. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $241.28. The firm has a market capitalization of $32.72 billion, a PE ratio of -103.55 and a beta of 1.75.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.26) EPS. On average, research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Natera

In related news, CFO Michael Burkes Brophy sold 1,867 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $190.64, for a total value of $355,924.88. Following the completion of the sale, the chief financial officer directly owned 64,126 shares in the company, valued at $12,224,980.64. The trade was a 2.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $198.60, for a total value of $595,800.00. Following the sale, the insider directly owned 112,061 shares in the company, valued at $22,255,314.60. This represents a 2.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 308,366 shares of company stock worth $63,050,068. 5.63% of the stock is currently owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.